A synthetic analog of alpha-melanocyte-stimulating hormone that stimulates melanogenesis, increasing skin pigmentation and providing photoprotection against UV radiation.
The study shows that the alpha‑MSH analog (melanotan‑I) changes skin cell (melanocyte) shape and makes them stick more tightly to the surrounding matrix, while a different molecule, endothelin‑1, does the opposite by boosting cell movement and reducing stickiness. These effects are linked to different internal signaling pathways, but the research doesn’t provide any direct health‑boosting protocol for longevity or performance.
Garg. P K PK; Alston. K L KL; Welsh. P C PC; Zalutsky. M R MR
Scientists tested two ways to stick a radioactive tag onto a skin‑pigment peptide used for targeting melanoma cells. The newer tagging method (using SIB) stuck better to the cells and broke down less, meaning less stray radioactivity in the body, but this is mainly a research tool, not a new way to use melanotan‑I for personal health.
Lúcio. Aline D AD; Vequi-Suplicy. Cíntia C CC; Fernandez. Roberto M RM; Lamy. M Teresa MT
The study shows a better way to look at how molecules sit on cell membranes using a fluorescent dye called Laurdan. By splitting the dye’s light signal into two parts, researchers can see tiny changes in membrane packing and water content more clearly than with older methods. They used this technique to compare a natural hormone (alpha‑MSH) and a stronger lab‑made version, finding that the stronger version makes the membrane surface stiffer, while the natural hormone mainly dries out the membrane surface.
de Angelis. E E; Sahm. U G UG; Ahmed. A R AR; Olivier. G W GW; Notarianni. L J LJ; Branch. S K SK; M...
Scientists discovered that mouse brain blood‑vessel cells have a receptor that binds the hormone alpha‑MSH, which melanotan‑I mimics. They showed the receptor is present but don’t know what it does, so there’s no clear way to use this info yet.
The study shows that a melanotropin peptide similar to melanotan‑I does not change norepinephrine release in a specific brain area, while opioid peptides do reduce it via mu‑opioid receptors. This means melanotan‑I probably won’t affect stress‑ or metabolism‑related norepinephrine pathways in the way some users might hope.
Barrett. P P; MacDonald. A A; Helliwell. R R; Davidson. G G; Morgan. P P
Scientists found a new melanocortin receptor in sheep that can bind alpha‑MSH‑like peptides, including a strong synthetic version called NDP‑MSH, and it triggers the usual cell signaling. The work is purely a lab discovery and doesn’t give any new instructions for using melanotan‑i or related peptides.
In a rat study, a synthetic version of the hormone alpha‑MSH (called (Nle4, D-Phe7)alpha‑MSH) was pumped directly into the brain after a type of brain injury that mimics Parkinson's disease. The treated rats showed better movement, less abnormal turning, and changes in dopamine receptors compared to rats that got just saline. However, the treatment was given by direct brain infusion, which isn’t practical for people, and the work was done in animals, not humans.
Goetz. A S AS; Andrews. J L JL; Littleton. T R TR; Ignar. D M DM
The paper describes a new lab method for quickly testing many compounds using cells that light up when a specific receptor is activated. Melanotan‑I was used as a test molecule to show the system works, but the study does not give any dosing, safety, or health‑benefit information for people.
Pritchard. L E LE; Armstrong. D D; Davies. N N; Oliver. R L RL; Schmitz. C A CA; Brennand. J C JC; W...
The study shows that a fragment of the protein agouti‑related protein (AGRP 83‑132) blocks the human melanocortin‑4 receptor (MC4‑R) in a straightforward, competitive way, without any fancy allosteric tricks. It also finds that many natural hormones derived from POMC, like different forms of melanocyte‑stimulating hormone, bind the same receptor with similar strength, meaning they could all play a role in controlling appetite.
Chluba. J J; Lima de Souza. D D; Frisch. B B; Schuber. F F
Scientists found that a short piece of the hormone alpha‑MSH can boost the delivery of DNA into cells, even when the cells don't have the usual hormone receptor. The peptide seems to act like a membrane‑disrupting helper, making gene‑transfer methods more efficient, but the work is purely lab‑based and not a health‑oriented protocol.
Frändberg. P A PA; Doufexis. M M; Kapas. S S; Chhajlani. V V
The study shows that specific parts of the MC1R receptor (the third intracellular loop) are needed for the receptor to talk to inside‑the‑cell proteins (G‑proteins). Changing these amino acids stops the normal signal (cAMP) even though the peptide still binds, meaning the receptor can't work properly without them.
Markison. Stacy S; Foster. Alan C AC; Chen. Chen C; Brookhart. Gregor B GB; Hesse. Amy A; Hoare. Sam...
Scientists gave mice a drug that blocks the MC4‑R receptor from the outside of the body. The drug made the mice eat more and burn fewer calories, and it helped keep muscle mass in mice with cancer‑related wasting. However, this work is done in rodents, uses a small‑molecule antagonist, and does not involve melanotan‑I, which is an MC1‑R agonist used by some biohackers.
The study found that some chemicals that block the usual MC4R signaling (the Gs‑cAMP pathway) can actually turn on a different pathway (ERK1/2 MAPK) in both normal and mutant MC4 receptors. This effect varies depending on the specific receptor mutation and the chemical used, but the research does not test melanotan‑I or give any dosing guidance.
Conway. S S; Canning. S J SJ; Barrett. P P; Guardiola-Lemaitre. B B; Delagrange. P P; Morgan. P J PJ
Scientists changed two building blocks (valine 208 and histidine 211) in a sheep melatonin receptor to see how they affect melatonin binding and signaling. All the altered receptors still showed up in cells, but they bound melatonin less tightly, and the ones with the histidine change stopped responding to melatonin altogether.
Barb. C R CR; Robertson. A S AS; Barrett. J B JB; Kraeling. R R RR; Houseknecht. K L KL
In pigs, activating brain receptors MC3/4 with a drug called NDP‑MSH reduced how much they ate, but blocking those receptors didn’t make them eat more. The study also found that a common MC4‑R mutation in pigs might change how these receptors work, and the drugs didn’t affect growth‑hormone or luteinising‑hormone levels.
Jiang. J J; Sharma. S D SD; Hruby. V J VJ; Bentley. D L DL; Fink. J L JL; Hadley. M E ME
The study shows that a synthetic version of the hormone alpha‑MSH (called [Nle4,D-Phe7]alpha‑MSH) can be attached to tiny latex beads, and these beads stick specifically to skin cells that have melanocortin receptors – mainly melanocytes (the cells that make pigment) and also keratinocytes. The binding can be blocked by the free hormone, proving the interaction is specific.
Preston. S F SF; Volpi. M M; Pearson. C M CM; Berlin. R D RD
In a lab study, a synthetic version of the hormone alpha‑MSH (similar to melanotan‑I) made melanoma cells grow thin, branch‑like extensions. This shape change was linked to two internal signals: raising cAMP levels and blocking a protein called PKC. Turning PKC on made the cells round up again, and the cells only went back to their original shape when they could make new proteins and RNA.
Scientists decoded a gene that controls pigment in woolly mammoths and found two versions—one that works well and one that works poorly—meaning ancient mammoths likely had both dark and light fur. This discovery is about ancient animal genetics, not about using the peptide melanotan‑i for health or performance.
Tafreshi. Narges K NK; Huang. Xuan X; Moberg. Valerie E VE; Barkey. Natalie M NM; Sondak. Vernon K V...
Scientists made a glowing molecule that sticks to a protein often found on melanoma skin cancers, letting surgeons see tumors more clearly during operations. This is a research tool, not a supplement or treatment you can use yourself.
Fan. Zhen-Chuan ZC; Sartin. James L JL; Tao. Ya-Xiong YX
The study examined two natural mutations in the pig version of the MC4R protein and found they behave just like the normal version, meaning they don’t change how the receptor works. This has no direct implications for using melanotan‑i or other peptides in humans.